There are concerns about the risks associated with CRISPR, a gene editing technology, with some studies finding potential risks to genome integrity. At the same time, some investors see high potential reward in CRISPR-related stocks, with some predicting significant growth. The technology's implications and potential applications, including its use in editing human genes, are being widely discussed and evaluated.